Literature DB >> 16405397

The human pre-B cell line Nalm-6 is highly proficient in gene targeting by homologous recombination.

Noritaka Adachi1, Sairei So, Susumu Iiizumi, Yuji Nomura, Kyoko Murai, Chie Yamakawa, Kiyoshi Miyagawa, Hideki Koyama.   

Abstract

Gene targeting provides a powerful means for analyzing gene function, as exemplified by knockout mouse studies and recent work with the highly recombinogenic chicken DT40 B-lymphocyte line. In human cultured cells, however, the low frequency of gene targeting is a serious barrier to efficiently generate knockout clones. Moreover, commonly used human cell lines are karyotypically abnormal or unstable. Here, we show using promoterless targeting constructs that Nalm-6, a human pre-B ALL cell line, is highly proficient for gene targeting by homologous recombination. Indeed, the efficiency of TP53 gene targeting in Nalm-6 appears nearly two orders of magnitude higher than that in HCT116, a colon cancer cell line popularly used for gene targeting. Expression analysis revealed a lack of MSH2 expression in this cell line. As Nalm-6 has a stable neardiploid karyotype with normal p53 status, our results underscore the usefulness of Nalm-6 for gene knockout studies in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405397     DOI: 10.1089/dna.2006.25.19

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  25 in total

1.  BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector.

Authors:  H Yamamoto; M Ishimura; M Ochiai; H Takada; K Kusuhara; Y Nakatsu; T Tsuzuki; K Mitani; T Hara
Journal:  Gene Ther       Date:  2015-08-17       Impact factor: 5.250

2.  Impaired cell adhesion, apoptosis, and signaling in WASP gene-disrupted Nalm-6 pre-B cells and recovery of cell adhesion using a transducible form of WASp.

Authors:  Rikiya Sato; Susumu Iiizumi; Eun-Sung Kim; Fumiko Honda; Sang-Kyou Lee; Noritaka Adachi; Hideki Koyama; Shuki Mizutani; Tomohiro Morio
Journal:  Int J Hematol       Date:  2012-02-05       Impact factor: 2.490

3.  Mutations to Ku reveal differences in human somatic cell lines.

Authors:  Kazi R Fattah; Brian L Ruis; Eric A Hendrickson
Journal:  DNA Repair (Amst)       Date:  2008-04-01

Review 4.  Mechanism of cluster DNA damage repair in response to high-atomic number and energy particles radiation.

Authors:  Aroumougame Asaithamby; David J Chen
Journal:  Mutat Res       Date:  2010-11-30       Impact factor: 2.433

Review 5.  CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.

Authors:  Rimsha Farooq; Khadim Hussain; Muhammad Tariq; Ali Farooq; Muhammad Mustafa
Journal:  J Appl Genet       Date:  2020-01-07       Impact factor: 3.240

6.  Use of DT40 conditional-knockout cell lines to study chromosomal passenger protein function.

Authors:  Xavier Fant; Kumiko Samejima; Ana Carvalho; Hiromi Ogawa; Zhenjie Xu; Zuojun Yue; William C Earnshaw; Sandrine Ruchaud
Journal:  Biochem Soc Trans       Date:  2010-12       Impact factor: 5.407

7.  Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.

Authors:  E Sotillo; T Laver; H Mellert; J M Schelter; M A Cleary; S McMahon; A Thomas-Tikhonenko
Journal:  Oncogene       Date:  2011-02-07       Impact factor: 9.867

Review 8.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

9.  Chromosomal manipulation by site-specific recombinases and fluorescent protein-based vectors.

Authors:  Munehiro Uemura; Youko Niwa; Naoki Kakazu; Noritaka Adachi; Kazuo Kinoshita
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

10.  NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.

Authors:  Eriko Toyoda; Shigehide Kagaya; Ian G Cowell; Aya Kurosawa; Keiichi Kamoshita; Kiyohiro Nishikawa; Susumu Iiizumi; Hideki Koyama; Caroline A Austin; Noritaka Adachi
Journal:  J Biol Chem       Date:  2008-07-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.